Skip to main content
Premium Trial:

Request an Annual Quote

Antibody Firm AxioMx Closes $2M Financing Round

Premium

Antibody firm AxioMx said this week that it has completed its initial financing round, raising more than $2 million from investors including Connecticut Innovations, Elm Street Ventures, and the company's founders.

Founded this year, AxioMx specializes in the discovery and development of custom recombinant antibodies, offering services including epitope mapping and antigen design as well as antibody screening, affinity maturation, optimization, and production.

The company uses proprietary phage display libraries and a "rapid liquid" screening and affinity maturation technique that it said can bring monoclonal antibody development times down from four to six months to less than four weeks.

The Scan

Driving Malaria-Carrying Mosquitoes Down

Researchers from the UK and Italy have tested a gene drive for mosquitoes to limit the spread of malaria, NPR reports.

Office Space to Lab Space

The New York Times writes that some empty office spaces are transforming into lab spaces.

Prion Pause to Investigate

Science reports that a moratorium on prion research has been imposed at French public research institutions.

Genome Research Papers on Gut Microbe Antibiotic Response, Single-Cell RNA-Seq Clues to Metabolism, More

In Genome Research this week: gut microbial response to antibiotic treatment, approach to gauge metabolic features from single-cell RNA sequencing, and more.